Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma

Saved in:
Bibliographic Details
Published inLeukemia Vol. 21; no. 12; pp. 2563 - 2566
Main Authors Saito, B, Shiozawa, E, Usui, T, Nakashima, H, Maeda, T, Hattori, N, Shimozuma, J, Adachi, D, Yamochi-Onizuka, T, Takimoto, M, Nakamaki, T, Ota, H, Tomoyasu, S
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.12.2007
Subjects
Aged
Aged, 80 and over
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
B-cell lymphoma
Cancer
Care and treatment
Chemotherapy
Combined Modality Therapy
Cyclophosphamide - administration & dosage
Disease-Free Survival
DNA microarrays
Doxorubicin - administration & dosage
Doxorubicin - analogs & derivatives
Drug Evaluation
Female
Genes, bcl-2
Genetic aspects
Germinal centers
Health aspects
Humans
Immunotherapy
Lymphocytes B
Lymphoma
Lymphoma, Large B-Cell, Diffuse - classification
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - genetics
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Lymphomas
Male
Middle Aged
NF-kappa B - antagonists & inhibitors
Prednisolone - administration & dosage
Retrospective Studies
Rituximab
Survival Analysis
Treatment Outcome
Vincristine - administration & dosage
Japan
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0887-6924
1476-5551
DOI:10.1038/sj.leu.2404844